QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COA5-Region Domestic ShippingPhase 3 Compound
What is Mazdutide 5mg?
Mazdutide (IBI362) is a weekly dual GLP-1R/GCGR (glucagon receptor) agonist developed by Innovent Biologics. The GLP-1R component provides appetite suppression and insulin secretion; the GCGR component adds direct hepatic fat mobilisation, thermogenesis via brown adipose tissue activation, and energy expenditure enhancement. Phase 3 GLORY trials in Chinese populations showed superior weight reduction vs semaglutide alone, with additional NAFLD benefit via the glucagon axis. Represents the same mechanistic approach as retatrutide’s GCGR component in a dual (rather than triple) agonist framework.
Research Applications
Dual GLP-1/GCGR Agonism Research
Enables isolation of GCGR contribution to weight loss when combined with GLP-1R agonism — comparison with GLP-1 monotherapy reveals additive glucagon receptor effects on fat mass, hepatic lipid, and energy expenditure.
NASH/NAFLD Research
The GCGR component provides direct hepatic fat mobilisation — mazdutide is studied in NAFLD models where glucagon axis activation reduces liver TG independently of appetite effects.
Comparison vs Semaglutide/Tirzepatide
Phase 3 data positions mazdutide as a distinct dual-agonist comparator. Research comparing GLP-1 mono vs GLP-1+GIP vs GLP-1+GCGR informs next-generation obesity pharmacology.
Quick Specs
| Product | Mazdutide 5mg × 10 Vials (50mg total) |
| Also known as | IBI362 |
| Target | GLP-1R + GCGR dual agonist |
| Format | Lyophilised powder, 10-vial kit |
| Purity | ≥99% HPLC, MS confirmed |
| Storage | −20°C lyophilised; 4°C reconstituted |
